Carillon Tower Advisers, an investment management firm, published its “Carillon Clarivest International Stock Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. At the start of the quarter, as compared to its MSCI EAFE® (NET) Index benchmark, the Carillon ClariVest International Stock Fund (the “Fund”) was most overweight the healthcare and information technology sectors, and most underweight materials and consumer staples. By the end of the quarter, the portfolio remained most overweight in the information technology and healthcare sectors and was most underweight in financials and real estate. Try to spend some time taking a look at the fund’s top 5 holdings to be informed about their best picks for 2022.
In its Q1 2022 investor letter, Carillon Clarivest International Stock Fund mentioned Merck & Co., Inc. (NYSE:MRK) and explained its insights for the company. Founded in 1891, Merck & Co., Inc. (NYSE:MRK) is a Readington Township, New Jersey-based multinational pharmaceutical company with a $235.5 billion market capitalization. Merck & Co., Inc. (NYSE:MRK) delivered a 21.52% return since the beginning of the year, while its 12-month returns are up by 18.55%. The stock closed at $93.13 per share on July 06, 2022.
Here is what Carillon Clarivest International Stock Fund has to say about Merck & Co., Inc. (NYSE:MRK) in its Q1 2022 investor letter:
“Merck (NYSE:MRK) is a global pharmaceutical and chemicals company based in Germany. Shares fell along with other vaccine-linked names after the U.S. Supreme Court blocked a rule mandating that businesses with more than 100 employees require those employed to either be vaccinated or tested weekly.”
Our calculations show that Merck & Co., Inc. (NYSE:MRK) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Merck & Co., Inc. (NYSE:MRK) was in 84 hedge fund portfolios at the end of the first quarter of 2022, compared to 80 funds in the previous quarter. Merck & Co., Inc. (NYSE:MRK) delivered a 9.60% return in the past 3 months.
In April 2022, we also shared another hedge fund’s views on Merck & Co., Inc. (NYSE:MRK) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q1 page.
Disclosure: None. This article is originally published at Insider Monkey.